IP Library Granted Patent US 8,309,723
Granted Patent B2
US 8,309,723 · App. 12/595,663 · Granted Nov 13, 2012

Preparation of Zopiclone and its enantiomerically enriched isomer

Assignee: Mylan Laboratories Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,309,723
App. No.
12/595,663
Granted
Nov 13, 2012
Kind
B2
Abstract

Present invention relates to an improved process for the preparation of Zopiclone and its enantiomerically enriched isomer (Eszopiclone). 6-(5-Chloropyridin-2-yl)-5-hydroxy-7-oxo-5,6-dihydropyrrolo[3,4-b]pyrazine is reacted with 1-chloro-carbonyl-4-methylpiperazine in the presence of alkali earth metal carbonates, hydroxides or oxides in a solvent medium to give Zopiclone. It is reacted with optically active acid in a mixture of water and water miscible organic solvent followed by work up to give Eszopiclone. The present invention also relates to process for the conversion of (R) or (S) Zopiclone to 6-(5-chloropyrid-2-yl)-5-hydroxy-7-oxo-5,6-dihydro-pyrrolo-[3,4-b]-pyrazine of the intermediate which can be converted to racemic Zopiclone.

Claims (9)

1. A process for the preparation of racemic Zopiclone, comprising the step of condensing 6-(5-chloropyrid-2-yl)-5-hydroxy-7-oxo-5,6-dihydropyrrolo[3,4-b]pyrazine with 1-chlorocarbonyl-4-methylpiperazine in the presence of dimethylaminopyridine, and at least one alkaline earth metal carbonate, hydroxide or oxide in a solvent medium to give racemic Zopiclone.

2. A process for the preparation of racemic Zopiclone according to claim 1 , wherein the alkaline earth metal carbonate is selected from the, group consisting of magnesium carbonate and calcium carbonate; the alkaline earth metal hydroxide is selected from the group consisting of magnesium hydroxide and calcium hydroxide; and the alka inc earth metal oxide is selected from the group consisting of magnesium oxide calcium oxide.

3. A process for the preparation of racemic Zopiclone according to claim 1 , wherein the solvent is selected from the group consisting of toluene, dichloromethane, dichloroethane, ethyl acetate, tetrahydrofuran, N,N′-dimethylformamide, N,N′-dimethylacetamide, dimethyl sulfoxide and mixtures thereof.

4. A process for the preparation of enantiomerically enriched Zopiclone, comprising the steps of:

(a) condensing 6-(5-chloropyrid-2-yl)-5-hydroxy-7-oxo-5,6-dihydropyrrolo[3,4-b]pyrazine with 1-chlorocarbonyl-4-methylpiperazine in the presence of dimethylaminopyridine and at least one alkaline earth metal carbonate, hydroxide or oxide in a solvent medium to give racemic Zopiclone, and

(b) reacting the obtained racemic Zopiclone with an optically active acid in a mixture of water and at least one water miscible organic solvent and recovering (R)-Zopiclone or (S)-Zopiclone.

5. A process for the preparation of (S)-Zopiclone according to claim 4 , wherein the at least one water miscible organic solvent is selected from the group consisting of ketones, nitriles and aprotic polar solvents.

6. A process for the preparation of (S)-Zopiclone according to claim 5 , wherein the ketone solvent is acetone, the nitrile solvent is selected from the group consisting of acetonitrile and propionitrile, and the aprotic polar solvent is selected from the group consisting of N,N′-dimethylformamide, N,N′-dimethylacetamide, and dimethyl sulfoxide.

7. A process for the preparation of (S)-Zopiclone according to claim 4 , wherein the optically active acid is selected from the group consisting of D-(+)-O,O′-dibenzoyltartaric acid, D-(+)-O,O′-p-toluyldibenzoyltartaric acid, and D-(+)-mandelic acid.

Assignments (4)
CHANGE OF NAME Recorded Jan 12, 2026
From: TIANISH LABORATORIES PRIVATE LIMITED
To: MATRIX PHARMACORP PRIVATE LIMITED
Reel/Frame 074322/0525 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 6, 2024
From: MYLAN LABORATORIES LIMITED
To: TIANISH LABORATORIES PRIVATE LIMITED
Reel/Frame 068861/0150 →
CHANGE OF NAME Recorded Feb 9, 2012
From: MATRIX LABORATORIES LIMITED
To: MYLAN LABORATORIES LIMITED
Reel/Frame 027678/0674 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 4, 2010
From: TYAGI, OM DUTT; SRIVASTAVA, TUSHAR KUMAR; PRASAD, VALLANKI SIVA RAM; RAGHO RANE, DNYANDEV; DURGA RAO, BANDI NAGA; SRINIVAS REDDY, DAGGULA
To: MATRIX LABORATORIES LTD.
Reel/Frame 024328/0255 →
Priority Claims (1)
IN 782/CHE/2007 · Apr 12, 2007 · national
Continuity (1)
Related Publication 20100056785A1 · Mar 4, 2010